IL221747A - Inhibits Sodium / Phosphate Co-Transmission through the Aryl Fluorophosphate Peripheral Membrane - Google Patents

Inhibits Sodium / Phosphate Co-Transmission through the Aryl Fluorophosphate Peripheral Membrane

Info

Publication number
IL221747A
IL221747A IL221747A IL22174712A IL221747A IL 221747 A IL221747 A IL 221747A IL 221747 A IL221747 A IL 221747A IL 22174712 A IL22174712 A IL 22174712A IL 221747 A IL221747 A IL 221747A
Authority
IL
Israel
Prior art keywords
preparation
arylfluorophosphate
medicaments
compounds
renal failure
Prior art date
Application number
IL221747A
Other languages
English (en)
Hebrew (he)
Original Assignee
Duophos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duophos filed Critical Duophos
Publication of IL221747A publication Critical patent/IL221747A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/141Esters of phosphorous acids
    • C07F9/146Esters of phosphorous acids containing P-halide groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/14Esters of phosphoric acids containing P(=O)-halide groups
    • C07F9/1406Esters of phosphoric acids containing P(=O)-halide groups containing the structure Hal-P(=O)-O-aryl

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL221747A 2010-03-05 2012-09-02 Inhibits Sodium / Phosphate Co-Transmission through the Aryl Fluorophosphate Peripheral Membrane IL221747A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31090210P 2010-03-05 2010-03-05
PCT/US2011/027232 WO2011109731A2 (en) 2010-03-05 2011-03-04 Arylfluorophosphate inhibitors of intestinal apical membrane sodium/phosphate co-transport

Publications (1)

Publication Number Publication Date
IL221747A true IL221747A (en) 2016-02-29

Family

ID=44542860

Family Applications (1)

Application Number Title Priority Date Filing Date
IL221747A IL221747A (en) 2010-03-05 2012-09-02 Inhibits Sodium / Phosphate Co-Transmission through the Aryl Fluorophosphate Peripheral Membrane

Country Status (13)

Country Link
US (2) US8921343B2 (https=)
EP (1) EP2542560B8 (https=)
JP (1) JP5819865B2 (https=)
CN (1) CN102918050B (https=)
AU (1) AU2011222551B2 (https=)
BR (1) BR112012022349B1 (https=)
CA (1) CA2792093C (https=)
ES (1) ES2561672T3 (https=)
IL (1) IL221747A (https=)
MX (1) MX2012010288A (https=)
NZ (1) NZ602703A (https=)
RU (1) RU2566757C2 (https=)
WO (1) WO2011109731A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011222551B2 (en) * 2010-03-05 2016-10-06 Duophos Arylfluorophosphate inhibitors of intestinal apical membrane sodium/phosphate co-transport
WO2017111087A1 (ja) * 2015-12-25 2017-06-29 ステラケミファ株式会社 モノフルオロリン酸エステル塩、その製造方法及びフッ素イオン放出性組成物
CN119431437B (zh) * 2024-11-04 2025-09-30 山东花物堂生物科技有限公司 丹皮酚磷酸酯及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2371910A1 (en) * 1999-01-21 2000-07-27 Brian E. Peerce Inhibitors of intestinal apical membrane na/phosphate co-transportation
US7119120B2 (en) * 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
ATE337326T1 (de) * 2002-03-19 2006-09-15 Genzyme Corp Hemmer des phosphattransports
RU2279676C2 (ru) * 2003-06-16 2006-07-10 Уральская государственная академия ветеринарной медицины Способ контроля над репаративным остеогенезом у животных
ES2633689T3 (es) * 2009-01-26 2017-09-22 Opko Ireland Global Holdings, Limited Regulación de fosfato con moléculas pequeñas
AU2011222551B2 (en) * 2010-03-05 2016-10-06 Duophos Arylfluorophosphate inhibitors of intestinal apical membrane sodium/phosphate co-transport

Also Published As

Publication number Publication date
US20130059822A1 (en) 2013-03-07
EP2542560A4 (en) 2014-10-15
HK1180692A1 (zh) 2013-10-25
AU2011222551A1 (en) 2012-09-27
BR112012022349A2 (pt) 2016-07-05
EP2542560B8 (en) 2015-12-30
NZ602703A (en) 2015-01-30
WO2011109731A2 (en) 2011-09-09
US8921343B2 (en) 2014-12-30
MX2012010288A (es) 2013-02-27
AU2011222551B2 (en) 2016-10-06
BR112012022349B1 (pt) 2019-09-24
CA2792093C (en) 2018-05-22
US9328128B2 (en) 2016-05-03
US20150080597A1 (en) 2015-03-19
ES2561672T8 (es) 2016-03-11
RU2012142336A (ru) 2014-04-10
JP5819865B2 (ja) 2015-11-24
EP2542560A2 (en) 2013-01-09
CN102918050A (zh) 2013-02-06
CA2792093A1 (en) 2011-09-09
ES2561672T3 (es) 2016-02-29
JP2013521337A (ja) 2013-06-10
RU2566757C2 (ru) 2015-10-27
CN102918050B (zh) 2015-07-01
WO2011109731A3 (en) 2012-03-01
EP2542560B1 (en) 2015-11-11

Similar Documents

Publication Publication Date Title
PL2672966T3 (pl) Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
IL225597A0 (en) Pharmaceutical preparation, methods of treatment and its uses
IL221160A (en) 4,2,1-triazine-3-amine derivatives, a process for their preparation and use for drug preparation
IL231591A0 (en) Converted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases
IL231382A (en) History of benzonitrile, their preparation and medications containing them
IL231386A (en) Pyrazolequinoline derivatives, their preparation and medical use
ZA201300100B (en) Indolizine derivatives,process for the preparation thereof and therapeutic use thereof
SG11201401907TA (en) Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
PL2720678T3 (pl) Kompozycja prekursorowa do dializy
PL2720700T3 (pl) Kompozycja prekursorowa do dializy
IL233238A0 (en) Sulphonylaminopyrrolidinone derivatives, their preparation and therapeutic use
IL219504A (en) Quinazoline Compounds, Pharmaceuticals Containing Them and Using It to Prepare Medicines to Treat Heart Failure with Congestion
ZA201206898B (en) Piperazinotriazines as pi3k inhibitors for use in the treatment antiproliferatiive disorders
TWI561256B (en) Dialysis precursor composition
PL2793902T3 (pl) Kompozycja prekursorowa do dializy
IL221747A (en) Inhibits Sodium / Phosphate Co-Transmission through the Aryl Fluorophosphate Peripheral Membrane
IL232385A (en) Use of Halopnate or Cephalic Acid Compounds to Treat Hyperoricemia in Patients with Gout, Hyperoricemia, or Renal Disorder
IL228891A (en) 3-carboxylic salts-n-ethyl n, n-dimethylpropane-1-amine for use in the treatment of cardiovascular disease
IL216746A (en) History of imidazole, the process of preparing them, and their use in the preparation of drugs for treatment
PT3539540T (pt) Inibidor de sglt2 1-cloro-4-(beta-d-glucopiranos-1-il)-2-[4-((s)-tetra-hidrofurano-3-iloxi)-benzil]-benzeno em combinação com insulina para utilização num método para redução do risco de hipoglicemia
ZA201307614B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
ZA201505093B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the treatment of atherosclerosis
HK1193342A (en) Pharmaceutical combination for use in the treatment of diabetes type 2
PL395184A1 (pl) Nowe pochodne benzimidazolu, sposób wytwarzania i zastosowanie pochodnych benzimidazolu
PL391810A1 (pl) Nowe sole ziprasidonu oraz sposoby ich otrzymywania

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed